The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index; 10 of the 138 sources its claims cite were checked for support.
Postural Orthostatic Tachycardia Syndrome: Mechanisms and New Therapies
Abstract
Postural orthostatic tachycardia syndrome (POTS) is a clinically heterogeneous disorder with multiple contributing pathophysiologic mechanisms manifesting as symptoms of orthostatic intolerance in the setting of orthostatic tachycardia (increase in heart rate by at least 30 beats per minute upon assuming an upright position) without orthostatic hypotension. The three major pathophysiologic mechanisms include partial autonomic neuropathy, hypovolemia, and hyperadrenergic state. Patients often will exhibit overlapping characteristics from more than one of these mechanisms. The approach to the treatment of POTS centers on treating the underlying pathophysiologic mechanism. Stockings, abdominal binders, and vasoconstrictors are used to enhance venous return in partial neuropathic POTS. Exercise and volume expansion are the main treatment strategies for hypo-volemic POTS. For hyperadrenergic POTS, beta-blockers and avoidance of norepinephrine reuptake inhibitors is important. Attempts should be made to discern which pathophysiologic mechanism(s) may be afflicting patients so that treatment regimens can be individualized.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Postural orthostatic tachycardia syndrome (POTS) is a clinically heterogeneous disorder defined by an upright heart rate increase of at least 30 bpm without orthostatic hypotension, with three major overlapping pathophysiologic endophenotypes: partial autonomic neuropathy, hypovolemia, and hyperadrenergic state. Treatment should be individualized to the underlying mechanism(s), using nonpharmacologic and pharmacologic strategies such as compression, volume expansion, exercise, beta-blockers, and avoidance of norepinephrine reuptake inhibitors.
Key findings
- POTS is estimated to affect 0.5–3 million individuals in the United States; >90% of patients are young, white women of childbearing age, and symptoms must persist for at least 3–6 months without another chronic condition or medication causing orthostatic intolerance.
- The three major endophenotypes are neuropathic POTS (partial autonomic neuropathy with lower-extremity, pelvic, and splanchnic blood pooling), hypovolemic POTS (13–22% lower plasma or blood volume, renin-aldosterone paradox, and Ang-II levels 2–3 times higher in some patients), and hyperadrenergic POTS (upright plasma norepinephrine often exceeding 800 pg/ml versus approximately 400–500 pg/ml in healthy controls).
- Treatment is mechanism-targeted: midodrine 5–10 mg acutely reduced heart rate from 108 bpm to 95 bpm in 13 POTS patients; 3 months of exercise training led 50–70% of completers to no longer meet POTS criteria, though only 41% of community patients completed a standardized program; hyperadrenergic POTS treatment includes beta-blockers, pyridostigmine, ivabradine, and avoidance of NRIs, SSRIs, or SNRIs.
- Patients often exhibit overlapping features from more than one endophenotype, and no single all-unifying pathophysiologic mechanism exists; POTS may be a final common pathway for several interrelated mechanisms.
Methods
- Narrative review of the literature on POTS mechanisms and therapies; no primary data collection, systematic search strategy, or meta-analysis is described.
- Synthesizes prior studies into three pathophysiologic endophenotypes and a treatment table, citing small prospective studies, randomized trials, retrospective analyses, and case series.
- Main analysis is qualitative mechanistic and therapeutic synthesis rather than formal quantitative analysis.
Limitations
- Stated in the paper: the exact prevalence of POTS is unknown; an all-inclusive pathophysiologic mechanism remains elusive; treatment knowledge has advanced mainly through small prospective studies; some agents are not well studied in POTS (e.g., fludrocortisone, droxidopa, ivabradine lacks a prospective comparator study); and exercise adherence is limited, with only 41% completing a standardized 3-month program.
- Evident from the text: as a narrative review, it does not systematically assess study quality, risk of bias, or publication bias, and many cited studies are small, retrospective, uncontrolled, or case series.
- Evident from the text: findings from special populations (e.g., astronauts, cosmonauts, Ehlers-Danlos syndrome patients, children) may not generalize to all POTS patients, and recommendations rely on synthesis and expert opinion rather than new empirical data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
90 Not checked yet · 12 Own interpretation · 4 Partly supported · 2 No basis given · 1 Supported · 1 Not supported · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While many conditions, such as mast cell activation disorders (9), Ehlers-Danlos syndrome (10, 11), deconditioning (12), and genetic mutations of norepinephrine transporters (13), coexist with POTS, their downstream effects also funnel into these three principal pathophysiologic mechanisms.”
What the sources say
- Not checked yetcites [9] source
- Not checked yetcites [10] source
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Other studies have also demonstrated that POTS patients have significantly greater decreases in thoracic and cerebral blood flow when compared to healthy controls during tilt (21, 23, 25-27).”
What the sources say
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
The Results (page unavailable) report that thoracic blood flow decreased during tilt in all subjects and that thoracic blood volume was significantly smaller in POTS patients than in controls at 35° and 70°. They do not establish a significantly greater decrease in thoracic blood flow in POTS patients, and the paper does not report cerebral blood flow during tilt. (LLM, conf=0.85)
- Partly supportedcites [23] sourceExperimental — accuracy not yet measured
The Upright Tilt Data results report a significantly reduced change in central blood volume in all POTS groups, but this is a measure of volume, not thoracic blood flow. They also report significantly decreased cerebral blood flow velocity during tilt only in the POTS-hyperventilation group, not in all POTS patients. (LLM, conf=0.88)
- Not checked yetcites [25] source
- Partly supportedcites [26] sourceExperimental — accuracy not yet measured
The HUT With Transcranial Doppler results report a significant decrease in cerebral blood-flow velocity during tilt in patients with idiopathic orthostatic intolerance. The paper does not establish that this decrease was greater than in healthy controls, and it does not report thoracic blood flow. Its Discussion also cautions that Doppler measures flow velocity rather than blood flow directly; page numbers are unavailable in our copy. (LLM, conf=0.88)
- Partly supportedcites [27] sourceExperimental — accuracy not yet measured
The Results (page unavailable) report a significantly greater decrease in cerebral blood-flow velocity during tilt in POTS subjects than in controls (19.5% versus 10.3%, P < 0.05). The paper does not report a corresponding comparison of thoracic blood flow, so it supports only the cerebral part of the claim. The Methods limit the studied POTS group to young, normocapnic subjects. (LLM, conf=0.90)
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“POTS patients will sometimes manifest features from more than one of the three major POTS endophenotypes (4).”
What the sources say
- Partly supportedcites [4] sourceExperimental — accuracy not yet measured
In “Need to Better Understand the Pathophysiologies Underlying POTS” (page unavailable), the paper says multiple underlying mechanisms can lead to POTS and several comorbid diagnoses can coexist in one patient. It does not identify three major POTS endophenotypes or state that patients manifest features of more than one; it instead calls for agreed-upon criteria for endophenotypes. (LLM, conf=0.81)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Not surprisingly, midodrine has been shown to be more effective in treating neuropathic POTS than hyperadrenergic POTS (56).”
What the sources say
- Supportedcites [56] source
The Discussion (Main findings; page not provided) reports that midodrine improved postural tachycardia versus placebo in neuropathic POTS but not hyperadrenergic POTS. The Summary and practical significance likewise says hyperadrenergic subjects responded similarly to midodrine and placebo. (LLM, conf=0.94)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Patients often will exhibit overlapping characteristics from more than one of these mechanisms.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Jacob et al. (18) demonstrated significantly impaired sympathetic nervous system activity in the lower extremities of POTS patients.”
What the sources say
- Not checked yetcites [18] source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In contrast, the amounts of norepinephrine released in the upper extremities in response to the same stimuli were no different between POTS patients and healthy controls.”
What the sources say
- Not checked yetcites [18] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The three major pathophysiologic mechanisms include partial autonomic neuropathy, hypovolemia, and hyperadrenergic state.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Stewart et al. (14-17) noted that pediatric patients with POTS had excessive pooling of blood in the lower extremities, primarily due to arteriolar dysregulation rather than inappropriately increased venous capacitance.”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Amounts of norepinephrine released at sympathetic nervous system synapses in the lower extremities in response to a cold pressor test, a nitroprusside infusion, and a tyramine infusion were markedly lower in POTS patients than in healthy controls.”
What the sources say
- Not checked yetcites [18] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 4
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“This cutaneous vasodilation is mediated by nitric oxide, as the addition of a nitric oxide synthase inhibitor blunts the vasodilation in both POTS patients and healthy controls to the same degree.”
What the sources say
- Disputedcites [28] sourceExperimental — accuracy not yet measured
The Results (Cutaneous Hyperemia and Endothelial Dysfunction) report that L-NAME blunted the thermal-hyperemia plateau in reference subjects but did not substantially affect the already attenuated plateau in a low-flow POTS patient; the grouped data confirmed this pattern. Normal-flow POTS responses were similar to reference responses, so the paper does not find the same degree of blunting across POTS patients and controls. (LLM, conf=0.92)
Checked by a reasoning model — may be wrong.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Exercise is the only intervention that has been shown to improve the aldosterone:renin ratio and increase plasma and blood volumes chronically (64).”
What the sources say
- Partly supportedcites [64] sourceExperimental — accuracy not yet measured
The Results (Exercise Training; page unavailable) report that three months of training increased plasma and blood volumes and modestly increased the aldosterone-to-renin ratio in POTS patients. The Results (Propranolol Treatment; page unavailable) report neither change with propranolol. The paper compares exercise with propranolol and placebo, so it does not establish that exercise is the only intervention capable of these effects. (LLM, conf=0.88)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Postural orthostatic tachycardia syndrome (POTS) is a clinically heterogeneous disorder with multiple contributing pathophysiologic mechanisms manifesting as symptoms of orthostatic intolerance in the setting of orthostatic tachycardia (increase in heart rate by at least 30 beats per minute upon assuming an upright position) without orthostatic hypotension.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“POTS should not be considered a disease but a clinical syndrome or phenotype, with the aforementioned signs (orthostatic tachycardia) and symptoms that worsen and improve with posture change.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
In the paper
“Mast cell degranulation causes a variety of vasoactive substances (histamine, prostaglandins, platelet-activating factor) to be released into the circulation, potentially causing excessive vasodilation and blood pooling in the lower extremities (31).”
What the sources say
- Not checked yetcites [31] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Under normal gravitational conditions, two weeks of strict bedrest resulted in a 17% reduction in plasma volume and a near 10% reduction in stroke volume (41).”
What the sources say
- Not checked yetcites [41] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This intolerance primarily manifests as excessive orthostatic tachycardia and reduced QSART (cholinergic sympathetic nerve sweat testing) responses when compared to those of healthy controls (30).”
What the sources say
- Not checked yetcites [30] source
plaincorrelationaln = 39- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Another study in 18 cosmonauts, who had spent several months on a space station, demonstrated that previously healthy individuals can experience moderate hemodynamic changes that almost meet some POTS criteria (average orthostatic heart rate increase by 26 bpm in the absence of orthostatic hypotension), with one individual meeting the orthostatic tachycardia criterion (heart rate increase by 31 b”
What the sources say
- Not checked yetcites [40] source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Administration of atomoxetine, a selective norepinephrine reuptake inhibitor (NRI), significantly increased the standing heart rate (from 105 bpm to 121 bpm) in POTS patients and resulted in greater symptoms of orthostatic intolerance (46).”
What the sources say
- Not checked yetcites [46] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Time to peak concentration is 1 h after administration, and pharmacologic effects last 4-5 h (55).”
What the sources say
- Not checked yetcites [55] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Iatrogenic inhibition of the norepinephrine transporter has also been shown to engender a POTS-like state, increase upright heart rate, and exacerbate symptoms in POTS patients (46-49).”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“While it can reduce orthostatic tachycardia in POTS patients to a similar extent as midodrine, it lacks a widely available oral dosage form and must be administered subcutaneously (60, 61).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“However, levels of norepinephrine in POTS patients can increase more than threefold, exceeding 800 pg/ml in many cases, while the increase in healthy controls after assuming an upright position is much more modest at approximately 400-500 pg/ml (36, 43).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Shannon et al. (13) discovered a single missense mutation (ALA457Pro) in the norepinephrine transporter gene ( SLC6A2 ) that resulted in a 98% loss of function in the transporter and was present in two identical twins with POTS.”
What the sources say
- Not checked yetcites [13] source
plaindirectn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Administration of a selective serotonin reuptake inhibitor (SSRI), sertraline, also appeared to acutely worsen symptoms in POTS patients, possibly due to nonselective inhibition of the norepinephrine transporter (47).”
What the sources say
- Not checked yetcites [47] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although this elevated norepinephrine state may be secondary to partial autonomic neuropathy or hypovolemia, the hallmark of this endophenotype is primary adrenergic excess.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Droxidopa is an orally active, synthetic prodrug of norepinephrine that reaches peak plasma concentration in 2 h (57).”
What the sources say
- Not checked yetcites [57] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Moreover, this dose did not cause hypertension nor significantly elevate blood pressure in this patient population (54).”
What the sources say
- Not checked yetcites [54] source
plainn = 13- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Regardless, the renin-aldosterone paradox and dysregulation of RAAS play a central role in the pathogenesis of this POTS endophenotype, and clearly would be worsened in the setting of any deconditioning, either voluntary or imposed.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Ang-II is the major effector of the RAAS axis, causing systemic vasoconstriction, raising blood pressure, promoting fluid retention, and is critical for maintaining fluid balance homeostasis through aldosterone secretion.
In the paper
“In healthy subjects, the supine plasma norepinephrine level is approximately 200 pg/ml, and upon standing, it doubles before it plateaus after 7.5 min (43).”
What the sources say
- Not checked yetcites [43] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Each twin had normal levels of supine plasma norepinephrine (269 pg/ml and 199 pg/ml), but standing plasma norepinephrine exceeded 900 pg/ml.”
What the sources say
- Not checked yetcites [13] source
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Fedorowski et al. (44) demonstrated that these autoantibodies, in addition to acting like a direct beta-agonist, can also upregulate sympathetic nervous activity through allosteric interactions with the beta-receptors.”
What the sources say
- Not checked yetcites [44] source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“It has not been well studied prospectively, and a retrospective analysis demonstrated only modest improvement in symptoms (58).”
What the sources say
- Not checked yetcites [58] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“POTS patients who participated in and completed 3 months of exercise training garnered a significant reduction in orthostatic tachycardia and experienced significant increases in blood volume (42).”
What the sources say
- Not checked yetcites [42] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In these studies, doses were initiated at 2.5 mg orally once or twice daily, and titrated up to 10 mg twice daily based on response or side effects with response rates between 60% and 78% (83, 84).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The clinically heterogeneous nature of POTS makes management inherently difficult.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
In the paper
“Patients also noted significant improvements in overall symptoms, specifically symptoms related to vision, tremulousness, and palpitations (69).”
What the sources say
- Not checked yetcites [69] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Raj et al. (78) demonstrated that the use of propranolol (instant release) at a 20 mg dose significantly reduced orthostatic tachycardia, and improved symptoms compared to placebo up to 4 h after administration.”
What the sources say
- Not checked yetcites [78] source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Many also report encountering initial skepticism during presentation, being given an incorrect psychiatric diagnosis, and having seen more than ten doctors before the correct diagnosis was made (2).”
What the sources say
- Not checked yetcites [2] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“but it did improve symptoms, at the expense of elevating blood pressure, in one study of treatment-refractory POTS patients (72).”
What the sources say
- Not checked yetcites [72] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Pyridostigmine enhances cholinergic activity at both the ganglionic nicotinic and the postganglionic muscarinic acetylcholine receptors, with a likely net increase in parasympathetic nervous system tone (3).”
What the sources say
- Not checked yetcites [3] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Improving clinician awareness can help improve all of these shortcomings (4).”
What the sources say
- Not checked yetcites [4] source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Lack of strong data and the high expense of erythropoietin limit its routine use in the treatment of POTS.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Targeting the underlying pathophysiologic mechanism in POTS improves clinical outcomes.
“The approach to the treatment of POTS centers on treating the underlying pathophysiologic mechanism.”
The paper relies on this without support.
The three POTS endophenotypes can be reliably distinguished in individual patients so that treatment can be individualized.
“Attempts should be made to discern which pathophysiologic mechanism(s) may be afflicting patients so that treatment regimens can be individualized.”
The paper relies on this without support.
Ang-II is the major effector of the RAAS axis, causing systemic vasoconstriction, raising blood pressure, promoting fluid retention, and is critical for maintaining fluid balance homeostasis through aldosterone secretion.
“Ang-II is the major effector of the RAAS axis, causing systemic vasoconstriction, raising blood pressure, and promoting fluid retention, and it is critical for maintaining fluid balance homeostasis through aldosterone secretion.”
The paper relies on this without support.
Midodrine is efficacious in treating hypovolemic POTS.
“Although midodrine does not directly expand plasma volume, it has been shown to be quite efficacious in treating hypovolemic POTS.”
The paper relies on this without support.
Oral clonidine has a short half-life and can cause a rapid onset-rapid offset phenomenon in some patients.
“Oral clonidine has a short half-life and can cause a rapid onset-rapid offset phenomenon in some patients.”
The paper relies on this without support.
Methyldopa has a longer half-life than oral clonidine and is often better tolerated by POTS patients.
“Methyldopa has a longer half-life than oral clonidine and is often better tolerated by POTS patients.”
Citations
Cites
Sheldon, R. S., Grubb, B. P., Olshansky, B., Shen, W.-K., Calkins, H., Brignole, M., Raj, S. R., Krahn, A. D., Morillo, C. A., Stewart, J. M., et al. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.03.029 · Cited by 1,013
Self-citationOrthostatic Intolerance and Tachycardia Associated with Norepinephrine-Transporter Deficiency
Shannon, J. R., Flattem, N. L., Jordan, J., Jacob, G., Black, B. K., Biaggioni, I., Blakely, R. D., & Robertson, D. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002243420803 · Cited by 594
Hunyady, L., & Catt, K. J. (2006) · Molecular Endocrinology · doi:10.1210/me.2004-0536 · Cited by 541
The neuropathic postural tachycardia syndrome
Jacob, G., Costa, F., Shannon, J. R., Robertson, R. M., Wathen, M., Stein, M., Biaggioni, I., Ertl, A., Black, B., & Robertson, D. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010053431404 · Cited by 398
Cardiac Atrophy After Bed-Rest Deconditioning: A Nonneural Mechanism for Orthostatic Intolerance
Levine, B. D., Zuckerman, J. H., & Pawelczyk, J. A. (1997) · Circulation · doi:10.1161/01.cir.96.2.517 · Cited by 371
Cardiac origins of the postural orthostatic tachycardia syndrome
Fu, Q., VanGundy, T. B., Galbreath, M. M., Shibata, S., Jain, M., Hastings, J. L., Bhella, P. S., & Levine, B. D. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.043 · Cited by 329
Shaw, B. H., Stiles, L. E., Bourne, K., Green, E. A., Shibao, C. A., Okamoto, L. E., Garland, E. M., Gamboa, A., Diedrich, A., Raj, V., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12895 · Cited by 326 · cited 3×
“The majority (>90%) of POTS patients are young, white women of childbearing age (2).”
BackgroundSelf-citationPostural Tachycardia Syndrome (POTS)
Raj, S. R. (2013) · Circulation · doi:10.1161/circulationaha.112.144501 · Cited by 320
Self-citationThe epidemic of orthostatic tachycardia and orthostatic intolerance
Robertson, D. (1999) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40480-x · Cited by 293
Raj, S. R., Biaggioni, I., Yamhure, P. C., Black, B. K., Paranjape, S. Y., Byrne, D. W., & Robertson, D. (2005) · Circulation · doi:10.1161/01.cir.0000160356.97313.5d · Cited by 286
Self-citationAutoimmune Basis for Postural Tachycardia Syndrome
Li, H., Yu, X., Liles, C., Khan, M., Vanderlinde‐Wood, M., Galloway, A., Zillner, C., Benbrook, A., Reim, S., Collier, D., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000755 · Cited by 255
Self-citationRaj, S. R., Black, B. K., Biaggioni, I., Paranjape, S. Y., Ramirez, M., Dupont, W. D., & Robertson, D. (2009) · Circulation · doi:10.1161/circulationaha.108.846501 · Cited by 225 · cited 1×
“(78) demonstrated that the use of propranolol (instant release) at a 20 mg dose significantly reduced orthostatic tachycardia, and improved symptoms compared to placebo up to 4 h after administration.”
BackgroundSelf-citationHyperadrenergic Postural Tachycardia Syndrome in Mast Cell Activation Disorders
Shibao, C., Arzubiaga, C., Roberts, L. J., Raj, S., Black, B., Harris, P., & Biaggioni, I. (2005) · Hypertension · doi:10.1161/01.hyp.0000158259.68614.40 · Cited by 220
Self-citationEffects of volume loading and pressor agents in idiopathic orthostatic tachycardia
Jacob, G., Shannon, J. R., Black, B., Biaggioni, I., Mosqueda-Garcia, R., Robertson, R. M., & Robertson, D. (1997) · Circulation · doi:10.1161/01.cir.96.2.575 · Cited by 206 · cited 2×
“Acute infusions of normal saline have been shown to afford rapid relief in patients with POTS crisis (8, 54), but this approach is not sustainable in the long-term due to the potential for vascular access complications (67).”
BackgroundHuman muscle sympathetic neural and haemodynamic responses to tilt following spaceflight
Levine, B. D., Pawelczyk, J. A., Ertl, A. C., Cox, J. F., Zuckerman, J. H., Diedrich, A., Biaggioni, I., Ray, C. A., Smith, M. L., Iwase, S., et al. (2002) · The Journal of Physiology · doi:10.1113/jphysiol.2001.012575 · Cited by 191
Fu, Q., VanGundy, T. B., Shibata, S., Auchus, R. J., Williams, G. H., & Levine, B. D. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.172262 · Cited by 175
Exercise and non-pharmacological treatment of POTS
Fu, Q., & Levine, B. D. (2018) · Autonomic Neuroscience · doi:10.1016/j.autneu.2018.07.001 · Cited by 174
Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome
Raj, S. R., Black, B. K., Biaggioni, I., Harris, P. A., & Robertson, D. (2005) · Circulation · doi:10.1161/circulationaha.104.497594 · Cited by 171
Self-citationStreeten, D. H. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114878 · Cited by 170
Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers-Danlos syndrome
De Wandele, I., Rombaut, L., Leybaert, L., Van de Borne, P., De Backer, T., Malfait, F., De Paepe, A., & Calders, P. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.12.006 · Cited by 168
Postural tachycardia syndrome: beyond orthostatic intolerance
Garland, E. M., Celedonio, J. E., & Raj, S. R. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0583-8 · Cited by 160
Self-citationTuvia, S., Atsmon, J., Teichman, S. L., Katz, S., Salama, P., Pelled, D., Landau, I., Karmeli, I., Bidlingmaier, M., Strasburger, C. J., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1179 · Cited by 160
Antiadrenergic autoimmunity in postural tachycardia syndrome
Fedorowski, A., Li, H., Yu, X., Koelsch, K. A., Harris, V. M., Liles, C., Murphy, T. A., Quadri, S. M. S., Scofield, R. H., Sutton, R., et al. (2017) · EP Europace · doi:10.1093/europace/euw154 · Cited by 151 · cited 3×
“Higher levels of autoantibodies against beta-1 and beta-2 adrenoreceptors have been detected in POTS patients versus healthy controls in serologic studies (32, 44).”
BackgroundStewart, J. M. (2002) · Circulation · doi:10.1161/01.cir.0000016348.55378.c4 · Cited by 138
Effect of standing on neurohumoral responses and plasma volume in healthy subjects
Jacob, G., Ertl, A. C., Shannon, J. R., Furlan, R., Robertson, R. M., & Robertson, D. (1998) · Journal of Applied Physiology · doi:10.1152/jappl.1998.84.3.914 · Cited by 134 · cited 1×
“However, levels of norepinephrine in POTS patients can increase more than threefold, exceeding 800 pg/ml in many cases, while the increase in healthy controls after assuming an upright position is much more modest at approximately 400–500 pg/ml (36, 43).”
BackgroundPostural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome
Roma, M., Marden, C. L., De Wandele, I., Francomano, C. A., & Rowe, P. C. (2018) · Autonomic Neuroscience · doi:10.1016/j.autneu.2018.02.006 · Cited by 133
Psychiatric profile and attention deficits in postural tachycardia syndrome
Raj, V, Haman, K. L., Raj, S. R., Byrne, D., Blakely, R. D., Biaggioni, I., Robertson, D., & Shelton, R. C. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.144360 · Cited by 131
Self-citationGeorge, S. A., Bivens, T. B., Howden, E. J., Saleem, Y., Galbreath, M. M., Hendrickson, D., Fu, Q., & Levine, B. D. (2016) · Heart Rhythm · doi:10.1016/j.hrthm.2015.12.012 · Cited by 127
Selective Norepinephrine Reuptake Inhibition as a Human Model of Orthostatic Intolerance
Schroeder, C., Tank, J., Boschmann, M., Diedrich, A., Sharma, A. M., Biaggioni, I., Luft, F. C., & Jordan, J. (2002) · Circulation · doi:10.1161/hc0302.102597 · Cited by 127 · cited 1×
“Administration of reboxetine, a norepinephrine transporter inhibitor, to healthy controls provoked hemodynamic changes consistent with POTS (48).”
BackgroundDeconditioning in patients with orthostatic intolerance
Parsaik, A., Allison, T. G., Singer, W., Sletten, D. M., Joyner, M. J., Benarroch, E. E., Low, P. A., & Sandroni, P. (2012) · Neurology · doi:10.1212/wnl.0b013e31826d5f95 · Cited by 111
Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience
KANJWAL, K., KARABIN, B., SHEIKH, M., ELMER, L., KANJWAL, Y., SAEED, B., & GRUBB, B. P. (2011) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2011.03047.x · Cited by 106 · cited 1×
“Further studies have also demonstrated long-term benefits with using pyridostigmine in POTS patients (81, 82).”
BackgroundSingle centre experience of ivabradine in postural orthostatic tachycardia syndrome
McDonald, C., Frith, J., & Newton, J. L. (2011) · Europace · doi:10.1093/europace/euq390 · Cited by 105
Ocon, A. J., Medow, M. S., Taneja, I., Clarke, D., & Stewart, J. M. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00138.2009 · Cited by 105
Vincent, S., Bieck, P. R., Garland, E. M., Loghin, C., Bymaster, F. P., Black, B. K., Gonzales, C., Potter, W. Z., & Robertson, D. (2004) · Circulation · doi:10.1161/01.cir.0000130847.18666.39 · Cited by 102
Regional blood volume and peripheral blood flow in postural tachycardia syndrome
Stewart, J. M., & Montgomery, L. D. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00086.2004 · Cited by 102
Anderson, J. W., Lambert, E. A., Sari, C. I., Dawood, T., Esler, M. D., Vaddadi, G., & Lambert, G. W. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00230 · Cited by 96 · cited 1×
“Given the high incidence of polypharmacy in POTS patients (10), coupled with the perception of increased depression in POTS patients (74), antidepressant use is likely high in this patient population.”
BackgroundPersistent splanchnic hyperemia during upright tilt in postural tachycardia syndrome
Stewart, J. M., Medow, M. S., Glover, J. L., & Montgomery, L. D. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00784.2005 · Cited by 95
Masuki, S., Eisenach, J. H., Johnson, C. P., Dietz, N. M., Benrud-Larson, L. M., Schrage, W. G., Curry, T. B., Sandroni, P., Low, P. A., & Joyner, M. J. (2007) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00927.2006 · Cited by 91
Pharmacotherapy for postural tachycardia syndrome
Miller, A. J., & Raj, S. R. (2018) · Autonomic Neuroscience · doi:10.1016/j.autneu.2018.04.008 · Cited by 91
Self-citationPOTS versus deconditioning: the same or different?
Joyner, M. J., & Masuki, S. (2008) · Clinical Autonomic Research · doi:10.1007/s10286-008-0487-7 · Cited by 90
Coffin, S. T., Black, B. K., Biaggioni, I., Paranjape, S. Y., Orozco, C., Black, P. W., Dupont, W. D., Robertson, D., & Raj, S. R. (2012) · Heart Rhythm · doi:10.1016/j.hrthm.2012.05.002 · Cited by 88
Self-citationHOELDTKE, R. D., & DAVIS, K. M. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-1-132 · Cited by 85
Okamoto, L. E., Diedrich, A., Baudenbacher, F. J., Harder, R., Whitfield, J. S., Iqbal, F., Gamboa, A., Shibao, C. A., Black, B. K., Raj, S. R., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07199 · Cited by 79
Self-citationFreitas, J., Santos, R., Azevedo, E., Costa, O., Carvalho, M., & Falcão de Freitas, A. (2000) · Clinical Autonomic Research · doi:10.1007/bf02281112 · Cited by 78
Ross, A. J., Ocon, A. J., Medow, M. S., & Stewart, J. M. (2014) · Clinical Science · doi:10.1042/cs20130222 · Cited by 78
Stewart, J. M., Glover, J. L., & Medow, M. S. (2006) · Clinical Science · doi:10.1042/cs20050254 · Cited by 77
Decreased Microvascular Nitric Oxide–Dependent Vasodilation in Postural Tachycardia Syndrome
Medow, M. S., Minson, C. T., & Stewart, J. M. (2005) · Circulation · doi:10.1161/circulationaha.104.526764 · Cited by 74
Splanchnic-mesenteric capacitance bed in the postural tachycardia syndrome (POTS)
Tani, H., Singer, W., McPhee, B. R., Opfer-Gehrking, T. L., Haruma, K., Kajiyama, G., & Low, P. A. (2000) · Autonomic Neuroscience · doi:10.1016/s1566-0702(00)00205-8 · Cited by 71
Local vascular responses affecting blood flow in postural tachycardia syndrome
Stewart, J. M., Medow, M. S., & Montgomery, L. D. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00429.2003 · Cited by 71
Segmental orthostatic fluid shifts
Diedrich, A., & Biaggioni, I. (2004) · Clinical Autonomic Research · doi:10.1007/s10286-004-0188-9 · Cited by 70
Cutaneous neuronal nitric oxide is specifically decreased in postural tachycardia syndrome
Stewart, J. M., Medow, M. S., Minson, C. T., & Taneja, I. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00600.2007 · Cited by 68
Effects of Norepinephrine Reuptake Inhibition on Postural Tachycardia Syndrome
Green, E. A., Raj, V., Shibao, C. A., Biaggioni, I., Black, B. K., Dupont, W. D., Robertson, D., & Raj, S. R. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000395 · Cited by 64 · cited 7×
“Hyperadrenergic POTS Avoiding NRIs, SSRIs, or SNRIs (46, 47, 49) These drugs can worsen tachycardia and/or symptoms in some patients Nonpharmacologic”
BackgroundInfluentialSelf-citationAbnormalities of angiotensin regulation in postural tachycardia syndrome
Mustafa, H. I., Garland, E. M., Biaggioni, I., Black, B. K., Dupont, W. D., Robertson, D., & Raj, S. R. (2011) · Heart Rhythm · doi:10.1016/j.hrthm.2010.11.009 · Cited by 62
Self-citationFu, Q., VanGundy, T. B., Shibata, S., Auchus, R. J., Williams, G. H., & Levine, B. D. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.151787 · Cited by 62
Acetylcholinesterase Inhibition in Patients With Orthostatic Intolerance
Singer, W., Opfer-Gehrking, T. L., Nickander, K. K., Hines, S. M., & Low, P. A. (2006) · Journal of Clinical Neurophysiology · doi:10.1097/01.wnp.0000229946.01494.4c · Cited by 60
Jordan, J., Shannon, J. R., Black, B. K., Paranjape, S. Y., Barwise, J., & Robertson, D. (1998) · Hypertension · doi:10.1161/01.hyp.32.4.699 · Cited by 56
Epigenetic Modification of the Norepinephrine Transporter Gene in Postural Tachycardia Syndrome
Bayles, R., KN, H., Lambert, E., Baker, E. K., Agrotis, A., Guo, L., Jowett, J. B. M., Esler, M., Lambert, G., & El-Osta, A. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.244343 · Cited by 56 · cited 1×
“Another study demonstrated that epigenetic modification of the SCL6A2 gene resulting in its downregulation was more prevalent in POTS patients than in healthy controls (45).”
BackgroundStewart, J. M., Pianosi, P., Shaban, M. A., Terilli, C., Svistunova, M., Visintainer, P., & Medow, M. S. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008854 · Cited by 55
Effects of exercise training on arterial-cardiac baroreflex function in POTS
Galbreath, M. M., Shibata, S., VanGundy, T. B., Okazaki, K., Fu, Q., & Levine, B. D. (2011) · Clinical Autonomic Research · doi:10.1007/s10286-010-0091-5 · Cited by 54
Stewart, J. M., & Weldon, A. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.89.4.1505 · Cited by 53
Neuronal and hormonal perturbations in postural tachycardia syndrome
Mar, P. L., & Raj, S. R. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00220 · Cited by 52
Self-citationIvabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience
Ruzieh, M., Sirianni, N., Ammari, Z., Dasa, O., Alhazmi, L., Karabin, B., & Grubb, B. (2017) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.13182 · Cited by 46
Mustafa, H. I., Raj, S. R., Diedrich, A., Black, B. K., Paranjape, S. Y., Dupont, W. D., Williams, G. H., Biaggioni, I., & Robertson, D. (2012) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.111.965343 · Cited by 44
Self-citationReflex vascular defects in the orthostatic tachycardia syndrome of adolescents
Stewart, J. M., & Weldon, A. (2001) · Journal of Applied Physiology · doi:10.1152/jappl.2001.90.6.2025 · Cited by 43
Droxidopa in the Treatment of Postural Orthostatic Tachycardia Syndrome
Ruzieh, M., Dasa, O., Pacenta, A., Karabin, B., & Grubb, B. (2017) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000468 · Cited by 42
Zhao, J., Du, S., Yang, J., Lin, J., Tang, C., Du, J., & Jin, H. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.05.039 · Cited by 41
Moon, J., Kim, D.-Y., Lee, W.-J., Lee, H. S., Lim, J.-A., Kim, T.-J., Jun, J.-S., Park, B., Byun, J.-I., Sunwoo, J.-S., et al. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0612-9 · Cited by 40
Postural tachycardia in hypermobile Ehlers-Danlos syndrome: A distinct subtype?
Miglis, M. G., Schultz, B., & Muppidi, S. (2017) · Autonomic Neuroscience · doi:10.1016/j.autneu.2017.10.001 · Cited by 38 · cited 2×
“Given the high incidence of polypharmacy in POTS patients (10), coupled with the perception of increased depression in POTS patients (74), antidepressant use is likely high in this patient population.”
BackgroundTreatment of orthostatic tachycardia with erythropoietin
Hoeldtke, R. D., Horvath, G. G., & Bryner, K. D. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80230-7 · Cited by 38
Postural orthostatic tachycardia syndrome and the potential role of mast cell activation
Doherty, T. A., & White, A. A. (2018) · Autonomic Neuroscience · doi:10.1016/j.autneu.2018.05.001 · Cited by 37 · cited 1×
“Mast cell degranulation causes a variety of vasoactive substances (histamine, prostaglandins, platelet-activating factor) to be released into the circulation, potentially causing excessive vasodilation and blood pooling in the lower extremities (31).”
BackgroundGaffney, F. A., Lane, L. B., Pettinger, W., & Blomqvist, C. G. (1983) · Chest · doi:10.1378/chest.83.2.436 · Cited by 36
Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome: A Systematic Review
Gee, M. E., Watkins, A. K., Brown, J. N., & Young, E. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0252-1 · Cited by 35
Moak, J. P., Leong, D., Fabian, R., Freedenberg, V., Jarosz, E., Toney, C., Hanumanthaiah, S., & Darbari, A. (2016) · Pediatric Cardiology · doi:10.1007/s00246-015-1274-6 · Cited by 34
Erythropoietin in the Treatment of Postural Orthostatic Tachycardia Syndrome
Kanjwal, K., Saeed, B., Karabin, B., Kanjwal, Y., Sheikh, M., & Grubb, B. P. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181ef621a · Cited by 34
Orthostatic heart rate responses after prolonged space flights
Tank, J., Baevsky, R. M., Funtova, I. I., Diedrich, A., Slepchenkova, I. N., & Jordan, J. (2011) · Clinical Autonomic Research · doi:10.1007/s10286-010-0106-2 · Cited by 32
Kpaeyeh, J., Mar, P. L., Raj, V., Black, B. K., Arnold, A. C., Biaggioni, I., Shibao, C. A., Paranjape, S. Y., Dupont, W. D., Robertson, D., et al. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000221 · Cited by 29
Self-citationZhao, J., Tang, C., Jin, H., & Du, J. (2014) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2014.04.032 · Cited by 27
Mar, P. L., Raj, V., Black, B. K., Biaggioni, I., Shibao, C. A., Paranjape, S. Y., Dupont, W. D., Robertson, D., & Raj, S. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512911 · Cited by 24
Self-citationMoving from the present to the future of Postural Tachycardia Syndrome – What we need
Raj, S. R., & Robertson, D. (2018) · Autonomic Neuroscience · doi:10.1016/j.autneu.2018.06.007 · Cited by 22
Self-citationRow, row, row your way to treating postural tachycardia syndrome
Raj, S. R. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.12.039 · Cited by 20
Self-citationDel Pozzi, A. T., Pandey, A., Medow, M. S., Messer, Z. R., & Stewart, J. M. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00194.2014 · Cited by 17
Patel, D. P., Nair, S., Suhagia, B. N., & Patel, B. M. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.09.005 · Cited by 15
Wang, H., Yang, G., Zhou, J., Pei, J., Zhang, Q., Song, X., & Sun, Z. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.04.056 · Cited by 12
Zhang, Z.-Y., Qian, L.-L., & Wang, R.-X. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00698 · Cited by 12
SANTOS, R. Q. D., SMIDT, L., SUZIGAN, B. H., DE SOUZA, L. V., & BARBISAN, J. N. (2013) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.12069 · Cited by 9
Research works printed but not linked: 3
- Low PA, 1995, Neurology, 45, S19
- Streeten DH, 1988, J. Lab. Clin. Med., 111, 326
- Raj S, 2014, Heart Rhythm, 11, S30
Cited by
Sorted by citations
Connelly‐Smith, L. S., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 751
ASIA syndrome and endocrine autoimmune disorders
Bragazzi, N. L., Hejly, A., Watad, ., Adawi, M., Amital, H., & Shoenfeld, Y. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101412 · Cited by 134
Taub, P. R., Zadourian, A., Lo, H. C., Ormiston, C. K., Golshan, S., & Hsu, J. C. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.029 · Cited by 122
Raj, S. R., Bourne, K. M., Stiles, L. E., Miglis, M. G., Cortez, M. M., Miller, A. J., Freeman, R. L., Biaggioni, I., Rowe, P. C., Sheldon, R. S., et al. (2021) · Autonomic Neuroscience · doi:10.1016/j.autneu.2021.102836 · Cited by 63
Self-citationEffect of High Dietary Sodium Intake in Patients With Postural Tachycardia Syndrome
Garland, E. M., Gamboa, A., Nwazue, V. C., Celedonio, J. E., Paranjape, S. Y., Black, B. K., Okamoto, L. E., Shibao, C. A., Biaggioni, I., Robertson, D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.005 · Cited by 65
Self-citation
Metadata
- Authors
- Mar, P. L., & Raj, S. R.
- Affiliations
- Saint Louis University (US)
- University of Calgary (CA)
- Venue
- Annual Review of Medicine
- Publisher
- Annual Reviews
- Published
- 2020-01-27
- Volume
- 71
- Issue
- 1
- Pages
- 235-248
- ISSN
- 0066-4219 (ISSN-L)
- 1545-326X
- OpenAlex
- W2967501582
- Semantic Scholar
- 392e517d5ad05ac895e6046186443346358a7d07
- Cited by
- 122
- References
- 85
- Citations by year
- 2026: 21 · 2025: 21 · 2024: 23 · 2023: 16 · 2022: 18 · 2021: 13 · 2020: 10
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annual Review of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000445)
- Canadian Institutes of Health Research (42426_1)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Syncope and Autonomic Disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Keywords
- postural orthostatic tachycardia syndrome, orthostatic intolerance, autonomic neuropathy, hypovolemia, hyperadrenergic state, pathophysiology, compression garments, abdominal binder, vasoconstrictors, exercise therapy, volume expansion, beta-blockers, norepinephrine reuptake inhibitors, personalized treatment
- MeSH terms
- Ivabradine, Adrenergic beta-Antagonists, Cardiovascular Agents, Clonidine, Combined Modality Therapy, Female, Humans, Male, Methyldopa, Quality of Life, Severity of Illness Index, Survival Analysis, Treatment Outcome, Risk Assessment, Postural Orthostatic Tachycardia Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
